• HER2-targeted therapy active in amplified but not mutated tumors

    Tucatinib and trastuzumab achieved responses in 38% of HER2-amplified cancers but only 6% of HER2-mutated cases, suggesting amplification status may better predict benefit from this combination. (NPJ Precis Oncol)